Mogamulizumab Clinical Trials
8 recruitingDrug
Phase 26Phase 12
Showing 1–8 of 8 trials
Recruiting
Phase 2
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Yale University22 enrolled2 locationsNCT05996185
Recruiting
Phase 1
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
Mycosis FungoidesCutaneous T Cell Lymphoma
University of Alabama at Birmingham10 enrolled1 locationNCT05414500
Recruiting
Phase 2
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
LymphomaT-cell LeukemiaT-Cell Leukemia/Lymphoma, Adult+1 more
Memorial Sloan Kettering Cancer Center134 enrolled7 locationsNCT06698003
Recruiting
Phase 1
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Recurrent Adult T-Cell Leukemia/LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Adult T-Cell Leukemia/Lymphoma+1 more
John Reneau12 enrolled1 locationNCT04848064
Recruiting
Phase 2
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Cutaneous T Cell LymphomaFungoides Mycosis Sezary Syndrome
University of Michigan Rogel Cancer Center23 enrolled1 locationNCT05956041
Recruiting
Phase 2
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
Primary Cutaneous T-Cell Non-Hodgkin LymphomaStage IB Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8+5 more
City of Hope Medical Center34 enrolled3 locationsNCT04930653
Recruiting
Phase 2
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Mycosis FungoidesSezary Syndrome
Stanford University30 enrolled1 locationNCT04256018
Recruiting
Phase 2
Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma
Stage IB-IIB Cutaneous T-Cell Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC43 enrolled13 locationsNCT04128072